Susan Acton discovered ACE2 while searching for new cardiovascular drugs. Decades later, she was surprised to see it popping up in the news once COVID took hold.
A new study finds that inherited genetic variation plays a role in who is likely to benefit from checkpoint inhibitors, which release the immune system’s brakes so it can attack cancer.
